Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy

Drugs of the Future

Volumn 26, Issue 11, 2001, Pages 1087-1092

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BIBX 1382; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; LAPATINIB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; NAUSEA; RASH; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0035685245     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.11.858717     Document Type: Review

References (39)

1. Oncogenic kinase signalling
2. Signal transduction pathway targets for anticancer drug discovery
3. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
4. EGF receptor
5. The epidermal growth factor receptor and its inhibition in cancer therapy
6. Transforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor
7. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. Correlations with proliferation and angiogenesis
8. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type
9. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma
10. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma
11. Epidermal growth factor-related peptides and their receptors in human malignancies
12. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
13. Protein tyrosine kinases and cancer
14. Prognostic significance of transforming growth factor-α in human esophageal carcinoma. Implication for the autocrine proliferation
15. Specificity within the EGF family/ErbB receptor family signaling network
16. Blocking oncogenic ras signaling for cancer therapy
17. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation
18. Receptor tyrosine kinase inhibitors
19. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
20. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a phase I study
21. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
22. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
23. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
24. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
25. Investigation of the effects of CP-358,774 on various human tumor specimens taken directly from patients
26. A phase II multicenter study of the epidermal growth factor receptor tyrosine kinase inhibitor CP-358,774 in patients with advanced squamous cell carcinoma of the head and neck
27. A phase II trial of the epidermal growth factor tyrosine kinase inhibitor CP-358,774 following platinum-based chemotherapy in patients with advanced non-small cell lung cancer
28. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma
29. A phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors
30. A phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on days 1, 8, and 15 every 28 days to patients with solid tumors
31. The HER tyrosine kinase inhibitor CI-1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein- mediated drug efflux
32. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor
33. EKB-569: A new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer
34. Combinatorial chemoprevention of intestinal neoplasia
35. Preclinical profile of PKI 166 - A novel and potent EGFR tyrosine kinase inhibitor for clinical development
36. BIBX1382BS, but not AG1478 or PD153035, inhibits the ErbB kinases at different concentrations in intact cells
37. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer
38. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
39. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors